Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

被引：0

作者：

Mario Tiribelli

Roberto Latagliata

Luigiana Luciano

Fausto Castagnetti

Antonella Gozzini

Giovanna Rege Cambrin

Mario Annunziata

Fabio Stagno

Patrizia Pregno

Francesco Albano

Elisabetta Abruzzese

Pellegrino Musto

Enrico Montefusco

Carmen Fava

Renato Fanin

Fabrizio Pane

Gianantonio Rosti

Massimo Breccia

Giuliana Alimena

Paolo Vigneri

机构：

[1] Azienda Ospedialiero-Universitaria,Division of Hematology and Bone Marrow Transplantation

[2] Sapienza University,Department of Cellular Biotechnology and Hematology

[3] Federico II University,Hematology Department

[4] University of Bologna,Institute of Hematology L. & A. Seràgnoli

[5] University of Florence,Department of Hematology

[6] University of Torino,Department of Clinical and Biological Sciences

[7] San Luigi Hospital,Division of Hematology and Stem Cell Transplantation Unit

[8] Cardarelli Hospital,Department of Clinical and Molecular Bio

[9] University of Catania,Medicine

[10] Azienda Ospedaliera Universitaria S. Giovanni Battista,Division of Hematology

[11] University of Bari,Department of Hematology

[12] Tor Vergata University Hospital,Department of Hematology

[13] Scientific Institute of Research and Cure,Department of Hematology and Stem Cell Transplantation

[14] S. Andrea Hospital,Department of Hematology

来源：

Annals of Hematology | 2013年 / 92卷

关键词：

CML; Elderly patients; Imatinib resistance; Dasatinib; BCR-ABL mutations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

引用

页码：179 / 183

页数：4

共 50 条

[1] Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
Tiribelli, Mario
Latagliata, Roberto
Luciano, Luigiana
Castagnetti, Fausto
Gozzini, Antonella
Cambrin, Giovanna Rege
Annunziata, Mario
Stagno, Fabio
Pregno, Patrizia
Albano, Francesco
Abruzzese, Elisabetta
Musto, Pellegrino
Montefusco, Enrico
Fava, Carmen
Fanin, Renato
Pane, Fabrizio
Rosti, Gianantonio
Breccia, Massimo
Alimena, Giuliana
Vigneri, Paolo
ANNALS OF HEMATOLOGY, 2013, 92 (02) : 179 - 183
[2] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
Tiribelli, M.
Latagliata, R.
Breccia, M.
Luciano, L.
Castagnetti, F.
Gozzini, A.
Cambrin, G. Rege
Annunziata, M.
Stagno, F.
Pregno, P.
Albano, F.
Abruzzese, F.
Musto, P.
Sora, F.
Ferrero, D.
Montefusco, E.
Cavazzini, F.
Binotto, G.
Fanin, R.
Pane, F.
Rosti, G.
Santini, V.
Fava, C.
Alimena, G.
Vigneri, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
[3] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
Hochhaus, A.
Branford, S.
Radich, J.
Mueller, M. C.
Shah, N.
Erben, P.
Ernst, T.
Acevedo, M.
Nicaise, C.
Hughes, T.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[4] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
Mueller, M. C.
Branford, S.
Radich, J.
Shah, N.
Erben, P.
Ernst, T.
Acevedo, M.
Nicaise, C.
Hughes, T.
Hochhaus, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 127 - 127
[5] Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Mueller, Martin C.
Cortes, Jorge E.
Kim, Dong-Wook
Druker, Brian J.
Erben, Philipp
Pasquini, Ricardo
Branford, Susan
Hughes, Timothy P.
Radich, Jerald P.
Ploughman, Lynn
Mukhopadhyay, Jaydip
Hochhaus, Andreas
BLOOD, 2009, 114 (24) : 4944 - 4953
[6] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Hughes, Timothy
Saglio, Giuseppe
Branford, Susan
Soverini, Simona
Kim, Dong-Wook
Mueller, Martin C.
Martinelli, Giovanni
Cortes, Jorge
Beppu, Lan
Gottardi, Enrico
Kim, Dongho
Erben, Philipp
Shou, Yaping
Haque, Ariful
Gallagher, Neil
Radich, Jerald
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4204 - 4210
[7] Impact of BCR-ABL mutations on patients with chronic myeloid leukemia
Hochhaus, Andreas
La Rosee, Paul
Mueller, Martin C.
Ernst, Thomas
Cross, Nicholas C. P.
CELL CYCLE, 2011, 10 (02) : 250 - 260
[8] Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Barbosa Pagnano, Katia Borgia
Miranda, Eliana Cristina
Delamain, Marcia Torresan
Duarte, Gislaine Oliveira
de Paula, Erich Vinicius
Lorand-Metze, Irene
de Souza, Carmino Antonio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11): : 728 - 733
[9] BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia
Khan, Adeel M.
Bixby, Dale L.
HEMATOLOGY, 2014, 19 (05) : 249 - 258
[10] Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
Agirre, X
Fontalba, A
Andreu, EJ
Odero, MD
Larróyoz, MJ
Montiel, C
Calasanz, M
Fernández-Luna, JL
Prósper, F
HAEMATOLOGICA, 2003, 88 (12) : 1425 - 1426

← 1 2 3 4 5 →